M&A Driven Events

“By the 2006-2010 period, almost all of the exits, upwards of 75% – regardless of size – were M&A driven events. The recent IPO window (2013/14) pushes the data a bit, but not enough to eliminate the dominance of M&A exits: More than 60% of the big >250M exits in our space in the last few years have been M&A.”

VC-Backed Biotech Exit routes: Percentage of "Exits" of any size from M&A vs IPO
VC-Backed Biotech Exit routes: Percentage of “Exits” of any size from M&A vs IPO
  • “IPOs used to be the only real game in town. Driving 67% of the exits and over 82% of the >250M exits in the late 1990s.”
  • “The share of big exits vs. all exits contributed by either path has converged over time. In the last 7 years, roughly identical percentages exits in the two charts above, suggesting that the relative contributions of IPOs and M&As at big and small valuations are similar.”

Source: Bruce Booth, “Acquisitions As the Silent Partner in Biotech Liquidity: IPO Vs. M&A Exit Paths,” Forbes, 10/27/1014

Two Recent Spectacular Wins!

Alios acquisition by J&J for $1.75B

SJA-MandA-fig-2

Seragon’s purchase by Roche/Genentech for $725M upfront and $1B in earn outs

SJA-MandA-fig-3
Bruce Booth, “Acquisitions As the Silent Partner in Biotech Liquidity: IPO Vs. M&A Exit Paths,” Forbes, 10/27/1014, NVCA

See SJA M&A/IPO Advisory Services